Editas Medicine
Genome-editing medicines for people living with serious diseases
Highlights
- New on EvolcAdded 2026-11-05
Recent signals
What changed at Editas Medicine in the last 6 months, newest first. Each line links to its public source.
- 28 Oct 2026 Leadership hire · Hiring Senior Director, Corporate Communications (Cambridge) apply.workable.com
- 9 Oct 2026 Leadership hire · Hiring Associate Director, Lipid Process Chemistry (Cambridge) apply.workable.com
- 7 Oct 2026 Leadership hire · Hiring Vice President, Regulatory Affairs (Cambridge) apply.workable.com
About Editas Medicine
Editas Medicine develops genomic medicines using CRISPR/Cas9 and CRISPR/Cas12a genome-editing systems. Its research focuses on hemoglobinopathies and in vivo gene editing, including cardiovascular diseases, sickle cell disease and beta thalassemia.
The company aims to discover, develop, manufacture and commercialize medicines for serious diseases. It advances cellular therapy programs through partnerships with Bristol Myers Squibb and Immatics.
Editas Medicine is headquartered in Cambridge, Massachusetts, and has a site in Boulder, Colorado. Open roles include positions in regulatory affairs, clinical development, medical affairs, corporate communications and process chemistry.
Product: Experimental CRISPR-based genomic medicines for serious diseases, including in vivo gene-editing and cellular therapy programs.
Jobs at Editas Medicine
Open roles at Editas Medicine in the Americas (5)
United States 5. From Editas Medicine's careers page or applicant tracking system; each role links to the employer.
- Vice President, Regulatory Affairs · Cambridge, United States
- Senior Medical Director, Clinical Development · Cambridge, United States
- Senior Director, Medical Affairs · Cambridge, United States
- Senior Director, Corporate Communications · Cambridge, United States
- Associate Director, Lipid Process Chemistry · Cambridge, United States
Leadership
- Gilmore O’Neill · President and Chief Executive OfficerSource: company website
- Amy Parison · Senior Vice President and Chief Financial OfficerSource: company website
- Tom Love · Vice President, PeopleSource: company website
More biotech & pharma companies
Gatesfoundation
Non-profit developing drugs, biologics and vaccines for tuberculosis and malaria in low- and middle-income countriesNew on EvolcGilead
CAR T-cell cancer therapies for patients with blood cancers, developed by Kite, a Gilead companyNew on EvolcGilead
Biopharmaceutical company developing and supplying medicines in virology, oncology and inflammation for patients worldwideNew on EvolcHansa Biopharma
Develops antibody-cleaving enzyme medicines for patients with rare immune-mediated diseases and transplant desensitisationHAYA Therapeutics
Develops RNA-guided medicines that target non-coding RNAs in disease, with Eli Lilly as a collaboration partnerIambic Therapeutics
AI-enabled drug discovery and therapeutic development for patients and pharmaceutical partnersRemote-friendly
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Recruiting
- WorkableHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.